March 27, 2018 • Page 3 of 3
“It is better to have a basket of them, so if one or two of the pharma or biotech companies fail, it doesn’t ruin the entire portfolio,” Gabelli's Jonas said.
This article was provided by Reuters.
Please log back in before proceeding.
There was an error logging in. Please try again.
Congrats! You are now logged in. Your exam is being submitted.